Somewhere between the promise of a medicine that has changed countless lives and the quiet fear of losing the sense that lets us read a face or a page, U.S. regulators have now asked the whole family of GLP-1 drugs to carry a new and sobering sentence. On Monday, the Food and Drug Administration announced that its warning about NAION, a rare condition in which the optic nerve loses blood flow and vision can fail permanently, will appear across the class, from Ozempic and Wegovy to Zepbound and Mounjaro. The cause remains unknown, the absolute risk remains small, and the drugmakers dispute that
FDA Adds Rare Vision-Loss Warning to GLP-1 Drugs Including Ozempic and Wegovy
Patients taking GLP-1 drugs face a rare risk of NAION, which can cause permanent and progressively worsening vision loss, even after stopping the medication.
Vision lost to NAION rarely comes back in any large measure
Mark
Why does this warning matter if the condition is so rare?
Mimi
Because the damage is serious and usually permanent. Dr. Rizzo says vision lost to NAION rarely comes back in any large measure, and it can keep worsening even after someone stops the drug.
Mark
And the numbers? How much higher is the risk?
Mimi
In the FDA's review of more than 125 trials, about 6 in 100,000 people on a GLP-1 for a year had it, versus under 4 in 100,000 on placebo or other glucose-lowering drugs.
Luke
Worth noting those are small absolute numbers, and the source gives the comparison as "under 4," not an exact figure. So the gap is real in the data but modest in size.
Mark
Does the FDA say the drugs cause it?
Mimi
The FDA says it has been reported with all of them, and Rizzo believes the evidence shows increased risk. Novo Nordisk disputes that a cause-and-effect relationship is established.
Luke
Right, so that's a live disagreement. The FDA also says the underlying cause isn't understood. A label warning isn't the same as a proven mechanism.
Mark
Is Rizzo telling people to stop taking them?
Mimi
No. He says the medicines have been profoundly beneficial to many people.
Luke
And we don't know yet how to reduce the risk. Rizzo said that himself, so there's no preventive step to point to beyond reporting symptoms quickly.
Mark
What should a patient do?
Mimi
If blurred vision, blind spots or distorted colors appear, contact a healthcare professional immediately.
O Pulso
- The FDA has added a permanent vision-loss warning to every GLP-1 drug label, touching a class of medicines taken by many millions of people.
- NAION strikes with little warning, and its damage to the optic nerve often cannot be reversed, even after the medication is stopped.
- Regulators found about 6 cases per 100,000 long-term GLP-1 users, against under 4 per 100,000 in comparison groups, while Novo Nordisk disputes any causal link.
- Eli Lilly is reviewing the update, and researchers are still searching for the mechanism and any way to reduce the risk.
- Patients noticing blurred vision, blind spots, or distorted colors are being urged to contact a clinician immediately.
Somewhere between the promise of a medicine that has changed countless lives and the quiet fear of losing the sense that lets us read a face or a page, U.S. regulators have now asked the whole family of GLP-1 drugs to carry a new and sobering sentence. On Monday, the Food and Drug Administration announced that its warning about NAION, a rare condition in which the optic nerve loses blood flow and vision can fail permanently, will appear across the class, from Ozempic and Wegovy to Zepbound and Mounjaro. The cause remains unknown, the absolute risk remains small, and the drugmakers dispute that a causal link has been proven, leaving patients to hold both the benefit and the uncertainty at once.
On Monday, U.S. health regulators announced that every GLP-1 medication will now carry a warning about a rare eye condition that can cause permanent vision loss. The Food and Drug Administration said the language will appear across the entire class, including Ozempic, Wegovy, Zepbound and Mounjaro, drugs prescribed for obesity, diabetes and several other conditions.
The condition, non-arteritic anterior ischemic optic neuropathy or NAION, results from reduced blood flow to the optic nerve. Its cause is not understood. The FDA's review began after a 2024 medical paper linked the condition to semaglutide, the active ingredient in Ozempic and Wegovy. Neuro-ophthalmologist Joseph Rizzo, a co-author of that paper, said he and his team had been working with the agency for some time, and that he was not surprised by the decision. He believes the evidence points to a real increase in risk, but he does not discourage patients from taking the drugs, which he described as profoundly beneficial to many people.
The FDA's analysis of more than 125 clinical trials found the condition in about 6 of every 100,000 patients who took a GLP-1 for at least a year, compared with under 4 per 100,000 on placebo or other diabetes drugs. NAION also occurs without any such medication, affecting roughly 2 to 10 in 100,000 adults over 50.
Rizzo described the hardest part for patients: the vision loss is often irreversible and can progress even after the drug is stopped, and no one yet knows how to lower the risk. The two eyes may also fare differently, so mild loss in one does not predict the other.
Novo Nordisk said the data do not establish cause and effect and that it remains confident in its medicines' benefit-risk balance, while acknowledging the profound toll NAION can take. Eli Lilly said it is evaluating the update and noted that the FDA cited no findings specific to its drugs.
For now, the guidance to patients is simple: sudden blurring, blind spots or changes in color warrant a prompt call to a clinician.
On Monday, U.S. health regulators announced that every GLP-1 medication will now carry a warning about a rare eye condition that can lead to permanent vision loss. The Food and Drug Administration said the new language will go onto the labeling of the entire drug class, including Ozempic and Wegovy, along with widely used brands such as Zepbound and Mounjaro. The class covers a dozen injectable and pill-based medications prescribed for obesity, diabetes and several other conditions.
The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. It results from reduced blood flow to the optic nerve and can cause significant loss of vision. The FDA said it has been reported with all GLP-1 drugs, though the underlying cause is not understood.
The agency's scientists began examining the issue after a 2024 medical paper linked NAION to certain patients taking semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy. One of that paper's co-authors, neuro-ophthalmologist Dr. Joseph Rizzo, told CBS News on Monday that he and his team had been working with the FDA for some time to gather and review data. He did not know the agency was ready to act, he said, but he was not surprised by the decision.
Rizzo believes the evidence shows GLP-1 use raises the risk of NAION. Still, he does not discourage patients from taking the drugs. "The medicines have really been profoundly beneficial to a large number of people," he said.
The numbers help frame the scale. NAION also occurs in people who take no GLP-1 drug, affecting roughly 2 to 10 of every 100,000 adults over 50, according to the American Academy of Ophthalmology. The FDA analyzed more than 125 clinical trials and found the problem in about 6 of every 100,000 patients who took a GLP-1 for at least a year. For people on a placebo or other glucose-lowering drugs, the rate was under 4 per 100,000. The agency also found reports of the condition in its electronic system for drug injuries and side effects.
The FDA listed the symptoms: blurred vision, blind spots, distorted colors and other visual disturbances. Anyone who notices such changes should contact a healthcare professional right away.
Rizzo described what makes the condition so hard on patients. The vision loss tends to be irreversible and can worsen progressively, even after someone stops the medication. "Usually when you lose vision, although there may be some mild degree of improvement, it's usually not a large degree of improvement," he said. He called it a great frustration for patients and their doctors that no one really knows how to mitigate the risk. He added that the two eyes can fare differently: mild loss in one eye does not predict the degree of loss in the other, which could be severe.
The drugmakers responded with caution. Novo Nordisk said it continues to believe the data do not establish a cause-and-effect relationship and remains confident in the benefit-risk profile of its GLP-1 medicines. It acknowledged that NAION can have a profound impact on patients and families, and said it continues to monitor safety and work with health authorities worldwide. Eli Lilly said it was carefully evaluating the update and would respond to the FDA promptly, noting that the agency's communication applies to all medicines with GLP-1 receptor agonist activity and cites no findings specific to Lilly's drugs.
What to watch now is how the companies respond to the FDA, and whether further research can explain the mechanism or find a way to reduce the risk. In the meantime, the guidance for patients is plain: sudden changes in vision warrant a prompt call to a clinician.
Citações Notáveis
The medicines have really been profoundly beneficial to a large number of people.— Dr. Joseph Rizzo, neuro-ophthalmologist
Novo Nordisk says the data do not establish a cause-and-effect relationship.— Novo Nordisk statement
Quer a matéria completa?
Leia o original em CBS News ↗
Health & Medicine